Loading…
Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress
Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary...
Saved in:
Published in: | Phytotherapy research 2022-10, Vol.36 (10), p.3911-3923 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3 |
container_end_page | 3923 |
container_issue | 10 |
container_start_page | 3911 |
container_title | Phytotherapy research |
container_volume | 36 |
creator | Ding, Yue Wang, Lei Liu, Bei Ren, Guoqing Okubo, Ryosuke Yu, Jing Zhang, Chaofeng |
description | Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects. |
doi_str_mv | 10.1002/ptr.7535 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2686058402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2723716431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</originalsourceid><addsrcrecordid>eNp1kc1qFzEUxYMo-LcVfISAGzdT8zGTmVnW4hdWWqSCu5BJbvpPySRjkqnOzkdw2efzSUxtQRBc3bv4nXMv5yD0jJIjSgh7uZR01He8e4B2lIxjQ7ueP0Q7Mna0aenw5TF6kvMVIWRkpN2hm1dpi2b1OmZ3CcEFrEqBsKoCGU8e4rxpF379-OmCWTUYvKx-jkGlDVs3parK-Nop7MLeTa64cImPP55_qIIZjKsuBs-QIej9NiuPYXFlD97VtSQVclXEejIYHL87o4q7BpxLgpwP0SOrfIan9_MAfX7z-uLkXXN69vb9yfFpozkTXaPNOE58onrkbDCkpcr2wIFrQWwniBCjZVpNQmgqekE1J60FqhijdrAEND9AL-58lxS_rpCLnF3W4L0KENcsmRgE6YaWsIo-_we9imsK9TvJesZ7KlpO_xrqmk5OYOWS3FwDk5TI24pkrUjeVlTR5g795jxs_-Xk-cWnP_xvCLuY7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2723716431</pqid></control><display><type>article</type><title>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</title><source>Wiley</source><creator>Ding, Yue ; Wang, Lei ; Liu, Bei ; Ren, Guoqing ; Okubo, Ryosuke ; Yu, Jing ; Zhang, Chaofeng</creator><creatorcontrib>Ding, Yue ; Wang, Lei ; Liu, Bei ; Ren, Guoqing ; Okubo, Ryosuke ; Yu, Jing ; Zhang, Chaofeng</creatorcontrib><description>Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects.</description><identifier>ISSN: 0951-418X</identifier><identifier>EISSN: 1099-1573</identifier><identifier>DOI: 10.1002/ptr.7535</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Alveoli ; AMPK activation ; Bleomycin ; bryodulcosigenin ; Collagen ; epithelial–mesenchymal transition ; Fibrosis ; Histopathology ; Inflammation ; Lung diseases ; Mesenchyme ; Molecular docking ; NOX4 protein ; Oxidative stress ; Pulmonary fibrosis ; SIRT1 protein ; Smad2 protein</subject><ispartof>Phytotherapy research, 2022-10, Vol.36 (10), p.3911-3923</ispartof><rights>2022 John Wiley & Sons Ltd.</rights><rights>2022 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</citedby><cites>FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</cites><orcidid>0000-0002-1504-305X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Ding, Yue</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Ren, Guoqing</creatorcontrib><creatorcontrib>Okubo, Ryosuke</creatorcontrib><creatorcontrib>Yu, Jing</creatorcontrib><creatorcontrib>Zhang, Chaofeng</creatorcontrib><title>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</title><title>Phytotherapy research</title><description>Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects.</description><subject>Alveoli</subject><subject>AMPK activation</subject><subject>Bleomycin</subject><subject>bryodulcosigenin</subject><subject>Collagen</subject><subject>epithelial–mesenchymal transition</subject><subject>Fibrosis</subject><subject>Histopathology</subject><subject>Inflammation</subject><subject>Lung diseases</subject><subject>Mesenchyme</subject><subject>Molecular docking</subject><subject>NOX4 protein</subject><subject>Oxidative stress</subject><subject>Pulmonary fibrosis</subject><subject>SIRT1 protein</subject><subject>Smad2 protein</subject><issn>0951-418X</issn><issn>1099-1573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kc1qFzEUxYMo-LcVfISAGzdT8zGTmVnW4hdWWqSCu5BJbvpPySRjkqnOzkdw2efzSUxtQRBc3bv4nXMv5yD0jJIjSgh7uZR01He8e4B2lIxjQ7ueP0Q7Mna0aenw5TF6kvMVIWRkpN2hm1dpi2b1OmZ3CcEFrEqBsKoCGU8e4rxpF379-OmCWTUYvKx-jkGlDVs3parK-Nop7MLeTa64cImPP55_qIIZjKsuBs-QIej9NiuPYXFlD97VtSQVclXEejIYHL87o4q7BpxLgpwP0SOrfIan9_MAfX7z-uLkXXN69vb9yfFpozkTXaPNOE58onrkbDCkpcr2wIFrQWwniBCjZVpNQmgqekE1J60FqhijdrAEND9AL-58lxS_rpCLnF3W4L0KENcsmRgE6YaWsIo-_we9imsK9TvJesZ7KlpO_xrqmk5OYOWS3FwDk5TI24pkrUjeVlTR5g795jxs_-Xk-cWnP_xvCLuY7A</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Ding, Yue</creator><creator>Wang, Lei</creator><creator>Liu, Bei</creator><creator>Ren, Guoqing</creator><creator>Okubo, Ryosuke</creator><creator>Yu, Jing</creator><creator>Zhang, Chaofeng</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1504-305X</orcidid></search><sort><creationdate>202210</creationdate><title>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</title><author>Ding, Yue ; Wang, Lei ; Liu, Bei ; Ren, Guoqing ; Okubo, Ryosuke ; Yu, Jing ; Zhang, Chaofeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alveoli</topic><topic>AMPK activation</topic><topic>Bleomycin</topic><topic>bryodulcosigenin</topic><topic>Collagen</topic><topic>epithelial–mesenchymal transition</topic><topic>Fibrosis</topic><topic>Histopathology</topic><topic>Inflammation</topic><topic>Lung diseases</topic><topic>Mesenchyme</topic><topic>Molecular docking</topic><topic>NOX4 protein</topic><topic>Oxidative stress</topic><topic>Pulmonary fibrosis</topic><topic>SIRT1 protein</topic><topic>Smad2 protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ding, Yue</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Ren, Guoqing</creatorcontrib><creatorcontrib>Okubo, Ryosuke</creatorcontrib><creatorcontrib>Yu, Jing</creatorcontrib><creatorcontrib>Zhang, Chaofeng</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Phytotherapy research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ding, Yue</au><au>Wang, Lei</au><au>Liu, Bei</au><au>Ren, Guoqing</au><au>Okubo, Ryosuke</au><au>Yu, Jing</au><au>Zhang, Chaofeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</atitle><jtitle>Phytotherapy research</jtitle><date>2022-10</date><risdate>2022</risdate><volume>36</volume><issue>10</issue><spage>3911</spage><epage>3923</epage><pages>3911-3923</pages><issn>0951-418X</issn><eissn>1099-1573</eissn><abstract>Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><doi>10.1002/ptr.7535</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-1504-305X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0951-418X |
ispartof | Phytotherapy research, 2022-10, Vol.36 (10), p.3911-3923 |
issn | 0951-418X 1099-1573 |
language | eng |
recordid | cdi_proquest_miscellaneous_2686058402 |
source | Wiley |
subjects | Alveoli AMPK activation Bleomycin bryodulcosigenin Collagen epithelial–mesenchymal transition Fibrosis Histopathology Inflammation Lung diseases Mesenchyme Molecular docking NOX4 protein Oxidative stress Pulmonary fibrosis SIRT1 protein Smad2 protein |
title | Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bryodulcosigenin%20attenuates%20bleomycin%E2%80%90induced%20pulmonary%20fibrosis%20via%20inhibiting%20AMPK%E2%80%90mediated%20mesenchymal%20epithelial%20transition%20and%20oxidative%20stress&rft.jtitle=Phytotherapy%20research&rft.au=Ding,%20Yue&rft.date=2022-10&rft.volume=36&rft.issue=10&rft.spage=3911&rft.epage=3923&rft.pages=3911-3923&rft.issn=0951-418X&rft.eissn=1099-1573&rft_id=info:doi/10.1002/ptr.7535&rft_dat=%3Cproquest_cross%3E2723716431%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2723716431&rft_id=info:pmid/&rfr_iscdi=true |